🔍

LAXMIDENTL - Laxmi Dental

📊 NSE: LAXMIDENTL 🏢 Healthcare 📅 Last Updated: 12/14/2025 9:12

📢 Recent Corporate Announcements

Laxmi Dental to Hold Non-Deal Roadshow (NDR) in Chennai on April 22, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Apr 2026, 04:26 PM

Laxmi Dental Limited has scheduled a Non-Deal Roadshow (NDR) to interact with institutional investors on April 22, 2026. The event is organized by Elara Capital and will feature 1x1 and group meetings in a physical format in Chennai. The company has stated that the discussions will be based on publicly available information and no unpublished price sensitive information (UPSI) will be shared. This move indicates management's proactive approach to engaging with the investment community.

Non-Deal Roadshow (NDR) scheduled for April 22, 2026, starting from 10:00 AM.
The event is organized by Elara Capital and will take place in Chennai.
Meetings will be conducted in a physical mode through 1x1 or group sessions.
Company confirms no unpublished price sensitive information (UPSI) will be discussed.

💡 Investors should monitor the company's website or exchange filings for any investor presentations that may be released in conjunction with this roadshow. No immediate action is required as this is a routine corporate interaction.

Laxmi Dental Receives BSE Approval for Listing 5 Lakh Shares Under ESOP Scheme 2024

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 10 Apr 2026, 07:46 PM

Laxmi Dental Limited has received in-principle approval from BSE for the listing of up to 5,00,000 equity shares under its Employee Stock Option Scheme (ESOP) 2024. These shares, with a face value of Rs. 2 each, will be issued and allotted upon the exercise of options by eligible employees. The approval follows compliance with SEBI's Share Based Employee Benefits and Sweat Equity Regulations, 2021. While this will lead to a minor dilution of equity, it is a standard practice for talent retention and aligning employee interests with company performance.

BSE granted in-principle approval for the listing of 5,00,000 equity shares.
The shares are issued under the Laxmi Dental Employee Stock Option Scheme 2024.
Each equity share has a face value of Rs. 2.
The company must comply with SEBI Regulation 10(c) for final trading permissions after allotment.
The approval was officially communicated by BSE on April 10, 2026.

💡 No immediate action is required as this is a routine regulatory update. Investors should note the potential for minor equity dilution as these options are exercised over the coming years.

Laxmi Dental Receives NSE In-Principle Approval for 5 Lakh ESOP Shares

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 09 Apr 2026, 06:07 PM

Laxmi Dental Limited has received in-principle approval from the National Stock Exchange (NSE) for the listing of up to 500,000 equity shares under its Employee Stock Option Scheme 2024. These shares have a face value of Rs. 2 each and will be allotted to employees upon the exercise of their options. The approval, dated April 8, 2026, is a standard regulatory step to facilitate the company's employee incentive program. This move is intended to align employee interests with shareholder value and aid in talent retention.

NSE granted in-principle approval for listing a maximum of 500,000 equity shares.
The shares are to be issued under the Laxmi Dental Employee Stock Option Scheme 2024.
Each equity share carries a face value of Rs. 2.
Final listing and trading approval are subject to compliance with SEBI (LODR) Regulations and other statutory norms.

💡 Investors should monitor the potential minor equity dilution as these options are exercised over time. No immediate action is required as this is a routine corporate procedure for employee compensation.

Laxmi Dental Approves Merger with Bizdent Devices and Cancels 32,538 ESOP Options

🟢 POSITIVE ⭐ 8/10

M&A 📅 26 Mar 2026, 08:18 PM

Laxmi Dental Limited has approved the amalgamation of its wholly-owned subsidiary, Bizdent Devices Private Limited, into itself to simplify group structure and achieve operational synergies. Bizdent specializes in aligners, sleep apnea devices, and sports guards, and the merger is expected to reduce administrative costs and improve financial strength. As Bizdent is a 100% subsidiary, no new shares will be issued, and there will be no change in the shareholding pattern. Additionally, the company reported the cancellation of 32,538 ESOP options and several key management and auditor appointments.

Approved Scheme of Amalgamation with wholly-owned subsidiary Bizdent Devices Private Limited
Forfeiture and cancellation of 32,538 ESOP options reported
No change in shareholding pattern as the transferor company is a 100% subsidiary
Appointment of Bathiya Advisors LLP as Internal Auditors for FY 2026-27
Redesignation of Mr. Mitesh Kariya as Chief Operating Officer – Illusion Dental

💡 The merger is a positive move for corporate simplification and cost rationalization. Investors should view this as a structural improvement that could lead to better operational margins in the long term.

Laxmi Dental Approves Merger of Wholly Owned Subsidiary Bizdent Devices

🟢 POSITIVE ⭐ 8/10

M&A 📅 26 Mar 2026, 08:15 PM

Laxmi Dental Limited has approved the Scheme of Amalgamation of its wholly-owned subsidiary, Bizdent Devices Private Limited, into itself to simplify group structure and achieve operational synergies. Bizdent Devices specializes in aligners, sleep apnea devices, and sports guards, and its integration is expected to reduce administrative and compliance costs. Since the subsidiary is 100% owned, no new shares will be issued, and there will be no change in the parent company's shareholding pattern. The board also appointed new internal auditors for FY 2026-27 and updated several corporate governance policies.

Approved merger of 100% subsidiary Bizdent Devices Private Limited with Laxmi Dental Limited.
No equity dilution as all shares of the transferor company will be cancelled upon amalgamation.
Appointment of Bathiya Advisors LLP as Internal Auditors for the financial year 2026-27.
Re-appointment of M/s. Abhay Subhash & Associates as Tax Auditors for FY 2025-26.
Redesignation of Mr. Mitesh Kariya as Chief Operating Officer – Illusion Dental.

💡 Investors should view the merger as a positive move toward corporate simplification and cost rationalization. Monitor the timeline for regulatory approvals from the Regional Director and Stock Exchanges to ensure smooth integration.

Laxmi Dental to Merge Subsidiary Bizdent Devices; Appoints New Internal Auditors

🟢 POSITIVE ⭐ 8/10

M&A 📅 26 Mar 2026, 08:13 PM

Laxmi Dental Limited has approved the merger of its wholly-owned subsidiary, Bizdent Devices Private Limited, into itself to streamline operations and reduce administrative costs. Bizdent Devices specializes in aligners and sleep apnea devices, and its consolidation is expected to create a stronger financial base and eliminate inter-company transactions. As Bizdent is a 100% subsidiary, no new shares will be issued, leaving the parent company's shareholding pattern unchanged. Additionally, the board appointed Bathiya Advisors LLP as Internal Auditors for FY 2026-27 and re-appointed Tax Auditors for FY 2025-26.

Board approved the Scheme of Amalgamation of Bizdent Devices Private Limited (WOS) with Laxmi Dental Limited.
The merger will result in the cancellation of the subsidiary's entire share capital with no new equity issuance.
Bathiya Advisors LLP appointed as Internal Auditors for FY 2026-27, effective April 1, 2026.
Abhay Subhash & Associates re-appointed as Tax Auditors for the financial year 2025-26.
Mr. Mitesh Kariya redesignated as Chief Operating Officer – Illusion Dental to strengthen leadership.

💡 Investors should view the internal merger as a positive move for operational efficiency and cost rationalization. Monitor the timeline for regulatory approvals from the Regional Director and Stock Exchanges to confirm the completion of the amalgamation.

Laxmi Dental Board Approves Merger of Wholly Owned Subsidiary Bizdent Devices

🟢 POSITIVE ⭐ 7/10

M&A 📅 26 Mar 2026, 07:49 PM

Laxmi Dental Limited has approved the Scheme of Amalgamation for its wholly-owned subsidiary, Bizdent Devices Private Limited, to merge into the parent company. The merger is designed to simplify the corporate structure, eliminate inter-company transactions, and reduce administrative and compliance costs. As Bizdent is a 100% subsidiary, no new shares will be issued, and the shareholding pattern of Laxmi Dental will remain unchanged. The board also approved the appointment of new internal auditors for FY 2026-27 and updated several corporate governance policies.

Merger of wholly-owned subsidiary Bizdent Devices Private Limited into Laxmi Dental Limited approved by the Board.
No new shares to be issued; the entire paid-up share capital of the subsidiary will be cancelled and extinguished.
Bizdent Devices specializes in manufacturing aligners, sleep apnoea devices, and sports guards.
M/s. Bathiya Advisors LLP appointed as Internal Auditors for the financial year 2026-27.
Mr. Mitesh Kariya redesignated as Chief Operating Officer – Illusion Dental effective March 26, 2026.

💡 Investors should view this as a positive move toward corporate simplification and operational efficiency. Monitor the company's upcoming quarterly results for any immediate impact on administrative cost reductions.

Laxmi Dental Limited Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Mar 2026, 05:19 PM

Laxmi Dental Limited has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is a standard procedure ahead of the declaration of the audited financial results for the quarter and financial year ending March 31, 2026. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be communicated separately.

Trading window closure effective from Wednesday, April 01, 2026.
Applies to all Designated Persons and their immediate relatives as per SEBI regulations.
Window to remain closed until 48 hours after the announcement of audited Q4 and FY26 results.
Board meeting date for financial result approval to be informed in due course.

💡 This is a routine regulatory announcement with no direct impact on stock valuation. Investors should await the announcement of the board meeting date to evaluate the company's year-end financial performance.

Laxmi Dental to Participate in Investec India Investor Conference on March 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Feb 2026, 11:52 AM

Laxmi Dental Limited has scheduled an interaction with institutional investors and analysts on March 11, 2026. The meeting is part of the Investec India Promoter & Founder Conference being held physically in Mumbai. The company will engage in 1x1 and group meetings starting from 10:00 AM. Management has clarified that no unpublished price sensitive information (UPSI) will be discussed during these sessions.

Meeting scheduled for March 11, 2026, starting at 10:00 AM IST.
Organized by Investec India as part of the Promoter & Founder Conference in Mumbai.
Interaction format includes both 1x1 and group meetings in physical mode.
Discussions will be strictly based on publicly available information as per SEBI regulations.

💡 Investors should monitor the company's website or exchange filings for any investor presentations that may be released following the conference. No immediate action is required as this is a routine corporate disclosure.

Laxmi Dental to Participate in Non-Deal Roadshow on March 5, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Feb 2026, 07:12 PM

Laxmi Dental Limited has announced a Non-Deal Roadshow (NDR) scheduled for March 5, 2026, in Pune. The event, organized by Elara Capital, will feature 1x1 and group meetings with institutional investors starting from 11:00 AM. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during these interactions. This move is part of the company's regular investor relations activities to engage with the financial community.

Non-Deal Roadshow (NDR) scheduled for March 5, 2026, in Pune.
Meetings will be conducted in 1x1 and group formats starting from 11:00 AM.
The event is being organized by Elara Capital for institutional investors.
Company confirms discussions will be based strictly on publicly available information.

💡 Investors should watch for any subsequent investor presentations or transcripts filed with the exchanges for insights into the company's strategy. No immediate trading action is required based on this routine disclosure.

Laxmi Dental Limited Releases Audio Recording of Q3FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 02:54 PM

Laxmi Dental Limited has informed the exchanges that the audio recording of its Q3FY26 earnings conference call is now available for public access. The call was held on February 11, 2026, at 9:00 AM IST and was organized by Elara Securities. This disclosure is a standard compliance requirement under SEBI Listing Regulations to ensure transparency for all shareholders. Investors can access the recording via the link provided on the company's official website to hear management's commentary on the quarter's performance.

Audio recording of the Q3FY26 earnings call released on February 11, 2026.
The conference call was organized by Elara Securities (India) Private Limited.
Filing made pursuant to Regulation 30(6) of SEBI Listing Regulations.
Direct MP3 link provided for investor access on the company's website.

💡 Investors should listen to the recording to understand management's outlook on the dental export market and specific financial drivers for Q3FY26. This is a routine update and does not change the fundamental view of the stock unless new material information is discovered in the call.

Laxmi Dental Q3 Revenue Up 7.1% YoY to ₹660 Mn; PAT Drops 59% on Exceptional Item

🔵 WATCH ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 09:49 PM

Laxmi Dental reported a 7.1% YoY revenue growth in Q3FY26, reaching ₹660.4 million, driven by strong international lab business growth of 25.5%. However, PAT declined significantly by 59.3% YoY to ₹19.6 million, primarily due to a one-time exceptional provision of ₹57.8 million for gratuity liabilities under new labour codes. EBITDA margins compressed to 10.6% from 15.6% a year ago, impacted by higher US tariffs (150 bps) and ESOP expenses. Management remains optimistic about Q4 recovery in the domestic market and normalization of pricing pressures in the aligner segment.

Revenue grew 7.1% YoY to ₹660.4 Mn in Q3FY26; 9M FY26 revenue up 14.3% to ₹2,039 Mn.
PAT fell 59.3% YoY to ₹19.6 Mn, impacted by a ₹57.8 Mn exceptional item for labour code compliance.
International dental lab business showed robust growth of 25.5% YoY, offsetting soft domestic performance.
EBITDA margins stood at 10.6%, affected by 150 bps impact from US tariffs and ₹16.14 Mn ESOP expenses.
Gross profit margins remained steady at 69.5% with sequential improvement due to lower low-margin scanner sales.

💡 Investors should monitor the recovery in domestic lab and aligner segments in Q4, as management indicates positive trends starting January 2026. While one-time costs hit the bottom line, the strong international growth and strategic positioning in digital dentistry remain key long-term drivers.

Laxmi Dental Q3FY26 Revenue Up 7% to ₹660 Mn; PAT Impacted by ₹57.8 Mn Exceptional Item

🔵 WATCH ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 09:41 PM

Laxmi Dental reported a 7.1% YoY revenue growth to ₹660.4 Mn for Q3FY26, supported by a robust 25.5% growth in its international dental lab business. However, net profit fell 59.3% YoY to ₹19.6 Mn, primarily dragged down by a one-time exceptional provision of ₹57.8 Mn for gratuity liabilities under the new labour code. EBITDA margins were also pressured by higher US tariffs (150 bps impact) and increased ESOP expenses. Despite these headwinds, the company saw a ₹32.2 Mn deferred tax credit from its US subsidiary and expects a stronger Q4 recovery.

Consolidated Revenue grew 7.1% YoY to ₹660.4 Mn in Q3FY26, with 9M FY26 revenue up 14.3% to ₹2,039 Mn.
International lab business delivered 25.5% YoY growth, while domestic lab business remained soft during the quarter.
EBITDA margin contracted to 10.6% from 15.6% YoY due to ₹16.1 Mn ESOP costs and global macroeconomic challenges.
A one-time exceptional provision of ₹57.8 Mn was recorded for gratuity past service liability under the new labour code.
Scanner sales grew 46% YoY in Q3, acting as a strategic lead generator for the higher-margin lab and aligner segments.

💡 Investors should focus on the normalization of US tariffs and the management's guidance for a robust Q4 recovery in domestic segments. While one-time provisions hurt the bottom line, the strong growth in international markets and digital dentistry (scanners) remains a positive long-term indicator.

Laxmi Dental Reports Q3 FY26 Revenue of ₹477.7M; Net Loss of ₹18.9M on Exceptional Labour Code Costs

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 07:10 PM

Laxmi Dental reported a year-on-year revenue growth of 11.7% for Q3 FY26, reaching ₹477.74 million. However, the company swung to a net loss of ₹18.90 million for the quarter, compared to a profit of ₹32.14 million in the same period last year. This loss was primarily driven by a one-time exceptional item of ₹51.56 million related to gratuity provisions under the New Labour Codes. For the nine-month period, net profit stands at ₹125.40 million, a significant decline from ₹215.99 million in the previous year.

Revenue from operations grew 11.7% Y-o-Y to ₹477.74 million, though it declined 11.1% on a Q-o-Q basis.
Reported a Net Loss of ₹18.90 million in Q3 FY26 vs a Net Profit of ₹32.14 million in Q3 FY25.
Recognized a one-time exceptional expense of ₹51.56 million for incremental gratuity impact following New Labour Code notifications.
Employee benefit expenses increased by 30% Y-o-Y to ₹200.91 million.
Utilized ₹669.78 million of IPO proceeds to date, with ₹611.92 million currently held in fixed deposits.

💡 Investors should treat the net loss as largely non-recurring due to the one-time labour code provision, but should monitor the sequential decline in revenue. Watch for stabilization in operating margins and the deployment of remaining IPO funds for growth.

Laxmi Dental Schedules Q3FY26 Earnings Conference Call for February 11, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 04 Feb 2026, 05:04 PM

Laxmi Dental Limited has announced its earnings conference call for the third quarter of FY26, scheduled for February 11, 2026, at 09:00 AM IST. The management team, including the CEO and CFO, will discuss the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. This call is a standard post-earnings event hosted by Elara Securities to provide transparency on company performance. Investors can participate via the provided dial-in numbers or the Diamond Pass registration link.

Earnings conference call scheduled for February 11, 2026, at 09:00 AM IST.
Discussion will cover unaudited financial results for Q3 and 9M ended December 31, 2025.
Top management including Chairperson Rajesh Khakhar and CEO Sameer Merchant will be in attendance.
The call is being coordinated by Elara Securities (India) Private Limited.
Universal dial-in numbers provided are +91 22 6280 1146 and +91 22 7115 8047.

💡 Investors should review the financial results once released and attend the call to understand management's commentary on margin trends and growth outlook. Focus on updates regarding the dental export business and domestic expansion plans.

View All LAXMIDENTL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Laboratory business revenue grew 28% YoY to INR 94.0 Cr in H1 FY26. Aligner solutions (Bizdent) grew 7% YoY to INR 38.8 Cr. Scanner sales saw a massive jump of 94.7% YoY in Q2 FY26, with units sold in H1 FY26 already exceeding the total sold in FY25.

Geographic Revenue Split

In H1 FY26, domestic revenue was INR 43.4 Cr (up 13% YoY) and international revenue was INR 36.1 Cr (up 25% YoY). International growth is outpacing domestic growth as the company leverages its US FDA registration for global expansion.

Profitability Margins

Gross profit for Q2 FY26 stood at INR 49.5 Cr, reflecting 14.5% YoY growth. PAT margin for Q2 FY26 was 11.8%, while H1 FY26 PAT margin was 12.2%. The company targets a long-term EBITDA margin of 20%.

EBITDA Margin

EBITDA margin for Q2 FY26 was 15.3%, while H1 FY26 EBITDA margin was higher at 16.6%. Margins were impacted by a 90 bps headwind due to US tariffs on international sales.

Capital Expenditure

The company undertook a CAPEX of approximately INR 6 Cr in H1 FY26. It has INR 64 Cr in unutilized IPO proceeds earmarked for future capacity expansion and automation.

Credit Rating & Borrowing

The company is currently debt-free, having paid off its entire debt in H1 FY26. This significantly reduced finance costs, which were INR 5.39 Cr in FY25, improving overall net profitability.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Zirconia blocks for crowns, polymer sheets (Taglus) for aligners, and digital scanner hardware components. Raw material costs are estimated at approximately 32% of revenue based on a 68% gross margin.

Import Sources

International markets, specifically the US and Germany, are key sources for technology and materials, as evidenced by US tariff impacts and participation in the IDS Germany event.

Capacity Expansion

The company is focusing on automation and R&D to enhance manufacturing capacities. It plans to deploy INR 64 Cr of unutilized IPO funds for future CAPEX to meet rising demand.

Raw Material Costs

Raw material costs represent approximately 32% of revenue. Procurement strategies focus on vertical integration (e.g., Taglus for aligners) to maintain high gross margins of ~68%.

Manufacturing Efficiency

The company is transitioning to digital dentistry; scanner sales jumped 94.7% YoY, which improves long-term efficiency by digitizing the impression-to-production cycle.

📈 Strategic Growth

Expected Growth Rate

20-25%

Growth Strategy

Growth will be achieved by scaling the branded product portfolio (Illusion Zirconia, Taglus), expanding manufacturing capacity through automation, and deepening international penetration following US FDA registration. The company uses lower-margin scanner sales as a strategic 'hook' to drive high-margin digital lab and aligner volumes.

Products & Services

Dental laboratory products (Zirconia crowns, bridges), clear aligners (Illusion Aligners), intra-oral scanners, and paediatric dental solutions (Kids-E-Dental).

Brand Portfolio

Illusion Zirconia, Illusion Aligners, Taglus, Bizdent, Vedia, and Kids-E-Dental.

New Products/Services

Intra-oral scanners are the primary new growth driver, with H1 FY26 sales already exceeding the total units sold in FY25. AI-driven diagnostics are also being integrated into the workflow.

Market Expansion

Targeting international markets with US FDA registration and EOU certification. Domestic expansion focuses on deepening the existing dental professional network.

Market Share & Ranking

Laxmi Dental is the second largest player in the domestic laboratory business and the largest export laboratory in India.

Strategic Alliances

Joint Ventures include Kids-E-Dental LLP (paediatric focus) and IDBG AI Dent (AI focus).

🌍 External Factors

Industry Trends

The industry is growing at ~20% and shifting toward digital dentistry and AI. Consolidation is occurring as organized players gain share from unorganized regional labs due to stricter regulatory norms and rising consumer awareness.

Competitive Landscape

Key organized competitors include DentCare (South India), alongside numerous regional unorganized labs that are currently facing consolidation pressures.

Competitive Moat

The moat is based on being the only integrated dental products company in India, providing a cost and quality advantage. Brand equity from celebrity endorsements and the scale of being the largest export lab provide durable competitive advantages.

Macro Economic Sensitivity

Highly sensitive to global trade policies; US tariffs resulted in a 90 bps margin compression in H1 FY26.

Consumer Behavior

Rising dental awareness and a shift toward branded, high-quality dental solutions are driving demand for the company's premium Illusion and Taglus brands.

Geopolitical Risks

Trade barriers and tariffs, particularly in the US market, pose a risk to the export-heavy laboratory business (INR 36.1 Cr in H1 FY26).

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by US FDA registration for exports, EOU (Export Oriented Unit) certification, and stricter domestic regulatory norms for dental medical devices.

Taxation Policy Impact

The effective tax rate was approximately 20.2% in FY25 (INR 64.5 Mn tax on INR 318.3 Mn PBT).

⚠️ Risk Analysis

Key Uncertainties

Key risks include global economic volatility affecting scanner adoption and potential fluctuations in international trade tariffs impacting export margins by ~90 bps.

Geographic Concentration Risk

International markets account for approximately 45% of core laboratory and aligner revenue, creating exposure to global trade dynamics.

Technology Obsolescence Risk

The company mitigates technology risk by aggressively investing in AI and digital scanners to stay ahead of the industry shift toward digital dentistry.